Advanced Lymphatic and Glymphatic Therapy for CBS/PSP

Advanced Lymphatic and Glymphatic Therapy for CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Advanced Lymphatic and Glymphatic Therapy for CBS/PSP</th>
</tr>
<tr>
<td class="label">Component</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Aquaporin-4 (AQP4)</td>
<td>Water channel on astrocyte endfeet</td>
</tr>
<tr>
<td class="label">Perivascular space</td>
<td>CSF-ISF exchange conduit</td>
</tr>
<tr>
<td class="label">Meningeal lymphatics</td>
<td>Drainage to cervical lymph nodes</td>
</tr>
<tr>
<td class="label">Arachnoid granulations</td>
<td>CSF outflow to venous sinus</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Sleep optimization</td>
<td>Maximize NREM duration</td>
</tr>
<tr>
<td class="label">Sedative hypnotics</td>
<td>Enhance slow-wave sleep</td>
</tr>
<tr>
<td class="label">Optogenetic activation</td>
<td>Direct neuronal silencing</td>
</tr>
<tr>
<td class="label">Transcranial stimulation</td>
<td>Induce slow oscillations</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">TGN-020</td>
<td>AQP4 inhibitor</td>
</tr>
<tr>
<td class="label">AQP4 modulators</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">VEGF-C delivery</td>
<td>Lymphangiogenesis</td>
</tr>
<tr>
<td c

Advanced Lymphatic and Glymphatic Therapy for CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Advanced Lymphatic and Glymphatic Therapy for CBS/PSP</th>
</tr>
<tr>
<td class="label">Component</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Aquaporin-4 (AQP4)</td>
<td>Water channel on astrocyte endfeet</td>
</tr>
<tr>
<td class="label">Perivascular space</td>
<td>CSF-ISF exchange conduit</td>
</tr>
<tr>
<td class="label">Meningeal lymphatics</td>
<td>Drainage to cervical lymph nodes</td>
</tr>
<tr>
<td class="label">Arachnoid granulations</td>
<td>CSF outflow to venous sinus</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Sleep optimization</td>
<td>Maximize NREM duration</td>
</tr>
<tr>
<td class="label">Sedative hypnotics</td>
<td>Enhance slow-wave sleep</td>
</tr>
<tr>
<td class="label">Optogenetic activation</td>
<td>Direct neuronal silencing</td>
</tr>
<tr>
<td class="label">Transcranial stimulation</td>
<td>Induce slow oscillations</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">TGN-020</td>
<td>AQP4 inhibitor</td>
</tr>
<tr>
<td class="label">AQP4 modulators</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">VEGF-C delivery</td>
<td>Lymphangiogenesis</td>
</tr>
<tr>
<td class="label">Mechanical massage</td>
<td>Flow enhancement</td>
</tr>
<tr>
<td class="label">Focused ultrasound</td>
<td>Lymphatic activation</td>
</tr>
<tr>
<td class="label">Lymphatic transplantation</td>
<td>Cellular therapy</td>
</tr>
<tr>
<td class="label">Current Medication</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>No direct interaction</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>No direct interaction</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Scientific Rationale</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Clinical Readiness</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Brain Delivery</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Safety Profile</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Total</td>
<td>23/50</td>
</tr>
</table>

The glymphatic system and meningeal lymphatic vessels provide the brain's primary waste clearance pathway. Dysfunction of these systems contributes to tau accumulation and propagation in CBS/PSP.

The Glymphatic System

The glymphatic system is a perivascular network that facilitates:

• CSF-ISF exchange: Cerebrospinal fluid enters brain parenchyma via periarterial spaces
• Waste clearance: Interstitial solutes, including tau aggregates, exit via perivenous pathways
• Sleep-dependent activity: Glymphatic clearance increases dramatically during NREM sleep

Key Components

Sleep-Dependent Clearance

NREM slow-wave sleep is the primary state for glymphatic clearance:

• Neuronal activity decreases → extracellular space expands by >60%
• Astrocytic AQP4 polarization facilitates bulk flow
• Tau and other aggregation-prone proteins are cleared

Therapeutic Strategies

Aquaporin-4 Targeting

AQP4 on astrocyte endfeet is critical for glymphatic function:

• Expression: Polarized to perivascular and subpial domains
• Dysfunction: Reduced perivascular AQP4 in aging and tauopathy
• Modulation: TGN-020 (AQP4 inhibitor), other small molecules

Clinical Candidates

Meningeal Lymphatic Modulation

Meningeal lymphatic vessels drain CSF and immune cells to cervical lymph nodes:

• Function: Essential for brain immune surveillance and waste clearance
• Impairment: Age-related decline contributes to neurodegeneration
• Enhancement: VEGF-C therapy, mechanical stimulation

Clinical Approaches

CBS/PSP Treatment Implications

For the CBS/PSP patient (50-year-old male, alpha-synuclein negative, on levodopa/rasagiline):

Drug Interaction Analysis

NET Assessment

Patient Action Items

See Also

• [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Tauopathy](/mechanisms/tau-pathology)
• [Sleep and Neurodegeneration](/mechanisms/sleep-neurodegeneration)

References

iliff2024, Brain-wide glymphatic pathway for the clearance of interstitial tau (2024)
mesquita2021, Functional aspects of meningeal lymphatics in ageing and neurodegeneration (2021)
nedergaard2020, Glymphatic failure as a final common pathway to dementia (2020)
xie2013, Sleep drives metabolite clearance from the adult brain (2013)
zhou2024, Aquaporin-4 targeted therapy for glymphatic dysfunction (2024)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
• [Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PIEZO1 and KCNK2
• [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style="color:#81c784;font-weight:600">0.60</span> · Target: ALOX12
• [Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DGAT1 and SOAT1
• [Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: AQP4
• [SASP-Driven Aquaporin-4 Dysregulation](/hypothesis/h-807d7a82) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: AQP4
• [Glymphatic System-Enhanced Antibody Clearance Reversal](/hypothesis/h-62e56eb9) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: AQP4

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;